566905-73-5

Upstream product

• 108-30-5 succinic acid anhydride 
• 27851-29-2 benzyl 2,3,4-tri-O-benzyl-D-glucopyranoside 
• 39687-20-2 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran-3,4,5-triol 
• 67890-29-3 benzyl 2,3,4,6-tetra-O-benzyl-β-D-gluco-pyranoside 
• 492-61-5 β-D-glucose 
• 4304-12-5 (2R,3R,4S,5S,6R)-2-(benzyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 27851-28-1 (2R,3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran 

Downstream Products

• 566905-76-8 N-benzyloxycarbonyl-3,4-dihydroxy-3,4-di-O-[(benzyl 2,3,4-tri-O-benzyl-β-D-glucopyranoside 6-yl)-succinyl]-phenylethylamine 
• 1187036-99-2 C₇₉H₈₀O₁₄ 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes

The new bifunctional cluster glucosides were designed and synthesized as liposome ligands for preparing novel liposome to achieve the effective delivery of drug formulations to brain by GLUT1. Docetaxel-loaded five liposomes were prepared successfully and tested in the animals. Results from the in vivo distribution study after i.v. administration of these five liposomes and blank-docetaxel indicated that the coupled liposomes Lip-1, Lip-2, Lip-3, Lip-5 exhibited excellent transport ability across the BBB. In particular, they significantly increased the level of docetaxel in brain compared to blank-docetaxel and Lip. Among them, Lip-5 showed higher brain concentration. Both pharmacokinetics and distribution study in mice confirmed that this novel brain targeting drug delivery system was a promising carrier to enhance brain delivery capacity for CNS drugs.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Synthesis of glycosyl derivatives as dopamine prodrugs: Interaction with glucose carrier GLUT-1

Glucosyl dopamine (DA) derivatives may represent a new class of DA prodrugs that would interact with glucose transporter GLUT-1, present in the blood-brain barrier, and generate DA in the brain. Therefore, compounds bearing the sugar moiety linked to eith